Zevra Therapeutics ZVRA
NASDAQ ZVRA
$10.13 -0.05 (-0.49%)
As of: Oct 2, 2026 · 10:38 AM EDT

Zevra Therapeutics (ZVRA) Preferred Stock Liabilities (2014)

Updated

Zevra Therapeutics' Preferred Stock Liabilities came in at $24.21 million for Q4 2014.

Analysis

Zevra Therapeutics (ZVRA) Preferred Stock Liabilities (2014) Analysis & Trends

  • Going back by year, Preferred Stock Liabilities was $37.1 million in FY2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Zevra Therapeutics 650.98 Mn -161.73 Mn 38.18 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 24.21 Mn
API Access

Zevra Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ZVRA&period=max&api_key=YOUR_API_KEY